Okuda M
Rhinology. 1984 Sep;22(3):171-82.
In several clinics we carried out a comparative double-blind study of ketotifen (HC) in 260 patients with perennial rhinitis in order to reveal the clinical efficacy, safety and usefulness. We administered two different doses of HC (0.5 mg X 2 and 1 mg X 2 daily), clemastine fumarate, CF (1.34 mg X 2 daily) and their placebos. The active drugs were always given in combination with their placebos during a period of 4 weeks. The results indicated that HC, especially HC 1 mg X 2, was superior to CF in efficacy and usefulness. Side-effects were mild and the frequency in which they occurred was similar to CF. In contrast to CF, HC showed an efficacy not only in sneezing and nasal discharge but also in nasal obstruction as well.
在几家诊所,我们对260例常年性鼻炎患者进行了酮替芬(HC)的比较双盲研究,以揭示其临床疗效、安全性和实用性。我们给予两种不同剂量的HC(每日0.5毫克×2次和1毫克×2次)、富马酸氯马斯汀(CF,每日1.34毫克×2次)及其安慰剂。在4周的时间里,活性药物总是与其安慰剂联合给药。结果表明,HC,尤其是1毫克×2次的HC,在疗效和实用性方面优于CF。副作用轻微,其发生频率与CF相似。与CF不同的是,HC不仅对打喷嚏和流鼻涕有效,对鼻塞也有效。